CING Insider Trading
Insider Ownership Percentage: 17.06%
Insider Buying (Last 12 Months): $1,490.50
Insider Selling (Last 12 Months): $842.34
Cingulate Share Price & Price History
Current Price: $4.51
Price Change: ▲ Price Increase of +0.17 (3.92%)
As of 02/14/2025 04:59 PM ET
Cingulate Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
8/15/2024 | Laurie Myers | COO | Sell | 202 | $4.17 | $842.34 | | |
3/15/2024 | Jennifer L Callahan | CFO | Buy | 55 | $27.10 | $1,490.50 | 2,333 | |
9/15/2023 | Jennifer L Callahan | Insider | Buy | 250 | $13.40 | $3,350.00 | 2,275 | |
8/11/2023 | Peter J Werth | Director | Buy | 91,157 | $11.00 | $1,002,727.00 | 139,916 | |
5/15/2023 | Jennifer L Callahan | Insider | Buy | 100 | $20.20 | $2,020.00 | 2,025 | |
5/12/2023 | Jennifer L Callahan | Insider | Buy | 200 | $21.60 | $4,320.00 | 1,925 | |
12/16/2022 | Shane J Schaffer | CEO | Buy | 500 | $20.40 | $10,200.00 | 2,075 | |
12/14/2022 | Jennifer L Callahan | Insider | Buy | 377 | $19.80 | $7,464.60 | 1,725 | |
12/13/2022 | Peter J Werth | Director | Buy | 1,446 | $19.60 | $28,341.60 | 48,758 | |
12/13/2022 | Shane J Schaffer | CEO | Buy | 86 | $20.20 | $1,737.20 | 911 | |
11/28/2022 | Jennifer L Callahan | Insider | Buy | 174 | $19.60 | $3,410.40 | 1,271 | |
11/23/2022 | Craig S Gilgallon | EVP | Buy | 178 | $16.80 | $2,990.40 | 477 | |
11/23/2022 | Laurie Myers | COO | Buy | 55 | $18.00 | $990.00 | 2,413 | |
11/22/2022 | Gregg Wm Givens | Director | Buy | 4,250 | $17.60 | $74,800.00 | 7,715 | |
9/8/2022 | Jennifer L Callahan | Insider | Buy | 175 | $30.00 | $5,250.00 | 1,097 | |
9/6/2022 | Peter J Werth | Director | Buy | 3,725 | $30.40 | $113,240.00 | 47,311 | |
6/1/2022 | Laurie Myers | COO | Buy | 10 | $23.60 | $236.00 | 2,335 | |
5/17/2022 | Laurie Myers | COO | Buy | 10 | $24.20 | $242.00 | 2,325 | |
5/6/2022 | Curtis Medeiros | Director | Sell | 876 | $25.40 | $22,250.40 | | |
3/17/2022 | Peter J Werth | Director | Buy | 1,350 | $35.80 | $48,330.00 | | |
3/16/2022 | Jennifer L Callahan | Insider | Buy | 95 | $27.80 | $2,641.00 | | |
3/16/2022 | Laurie Myers | COO | Buy | 17 | $28.00 | $476.00 | | |
3/14/2022 | Craig S Gilgallon | EVP | Buy | 298 | $27.60 | $8,224.80 | | |
3/14/2022 | Gregg Wm Givens | Director | Buy | 450 | $26.40 | $11,880.00 | | |
3/14/2022 | Horn Louis G Van | CFO | Buy | 750 | $26.80 | $20,100.00 | | |
3/14/2022 | Jennifer L Callahan | Insider | Buy | 600 | $29.20 | $17,520.00 | | |
Cingulate Institutional Trading History
Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
---|
2/12/2025 | Geode Capital Management LLC | 27,323 | $0.14M | 0.0% | N/A | 0.851% |  |
2/10/2025 | Commonwealth Equity Services LLC | 43,022 | $0.21M | 0.0% | +281.5% | 1.340% |  |
1/21/2025 | AlphaMark Advisors LLC | 5,010 | $25K | 0.0% | +50,000.0% | 0.156% |  |
11/15/2024 | Jane Street Group LLC | 21,031 | $0.11M | 0.0% | N/A | 0.655% |  |
8/15/2024 | Armistice Capital LLC | 490,000 | $0.16M | 0.0% | N/A | 6.671% |  |
11/15/2023 | Armistice Capital LLC | 754,792 | $0.54M | 0.0% | N/A | 4.820% |  |
10/23/2023 | Commonwealth Equity Services LLC | 100,771 | $71K | 0.0% | N/A | 0.643% |  |
5/5/2023 | Prime Capital Investment Advisors LLC | 48,262 | $48K | 0.0% | N/A | 0.413% |  |
11/8/2022 | Eagle Asset Management Inc. | 107,527 | $0.12M | 0.0% | +124.5% | 0.951% |  |
5/12/2022 | Eagle Asset Management Inc. | 47,895 | $94K | 0.0% | N/A | 0.424% |  |
5/5/2022 | Lynwood Capital Management Inc. | 225,994 | $0.45M | 0.5% | +80.8% | 1.998% |  |
2/14/2022 | Altium Capital Management LP | 83,931 | $0.23M | 0.1% | N/A | 0.742% |  |
Data available starting January 2016
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Read More on Cingulate
Volume
102,173 shs
Average Volume
138,143 shs
Market Capitalization
$14.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Cingulate?
Who are the major institutional investors of Cingulate?
Which major investors are buying Cingulate stock?
During the last quarter, CING stock was bought by institutional investors including:
- Commonwealth Equity Services LLC
- Geode Capital Management LLC
- AlphaMark Advisors LLC
In the previous year, these company insiders have bought Cingulate stock:
- Peter J Werth (Director)
- Jennifer L Callahan (CFO)
- Jennifer L Callahan (Insider)
Learn More investors buying Cingulate stock.